Scotiabank analyst George Farmer maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of ...

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with ...

In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes into consideration the $4.8 billion it paid to acquire the gene therapy ...

It's hard watching a former local darling get restructured, but federal funding blocks and a lack of local investors are more front-of-mind.

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in ...

Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8 billion deal, ahead of a regulatory deadline later today in the US.

Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series of ...

Spark had an unspecified number of layoffs last summer after discontinuing work on several early-stage products, Endpoints News reported. The company now employs “more than 600,” Bradley said ...

Shares of Lava Therapeutics surged on Tuesday as the company said it is exploring strategic options that could include a sale or merger. Lava Therapeutics, an immuno-oncology company with ...

Building a climate-controlled warehouse and logistics facility for United Therapeutics in North Carolina’s Research Triangle was a matter of power management and careful planning. The facility ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...